An Autonomous Robotic Phlebotomy Device: Extended Analytical Validation and Real-World Hemolysis Assessment

Background/Objectives: Automated phlebotomy may improve preanalytical quality and access to venous blood testing. Prior work evaluating the Aletta Autonomous Robotic Phlebotomy Device (ARPD) demonstrated analytical equivalence. This study expanded the initial analytical validation to additional blood collection tubes and analytes and also assessed real-world hemolysis rates. Methods: The study was conducted in three hospital outpatient phlebotomy departments, including a site with a high prevalence of (hemato-)oncology patients. The within-subject analytical validation study included Greiner VACUETTE (Cohort 1) and BD Vacutainer (Cohort 2) serum, lithium heparin, and EDTA tubes. Equivalence of potassium, lactate dehydrogenase, hemolysis index, and complete blood count (CBC) with differential between paired ARPD-collected and manually collected samples was assessed using Passing–Bablok regression. Real-world ARPD hemolysis (>0.5 g/L free hemoglobin) rates were determined in a separate cohort (Cohort 3) and compared with site-specific manual hemolysis rates. Results: In the analytical validation study, 119 patients were included in the analysis (Cohort 1, n = 52; Cohort 2, n = 67). All tests met the predefined acceptability criteria. The hemolysis index was statistically significantly lower in ARPD-collected lithium heparin samples in Cohort 1. In real-world use (1368 ARPD venipunctures), the ARPD hemolysis rate was 0.0% (95% CI: 0.0–0.3%), significantly lower than manual phlebotomy (1.6%, p = 0.025). Conclusions: The study demonstrated analytical equivalence in a clinically complex population and found reduced ARPD hemolysis rates. The results further substantiate that the ARPD could improve patient care by reducing preanalytical errors.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-11-17
DOI
https://doi.org/10.3390/diagnostics16223822
Primary Topic
Clinical Laboratory Practices and Quality Control
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

An Autonomous Robotic Phlebotomy Device: Extended Analytical Validation and Real-World Hemolysis Assessment

Michael A. Fouraux, Thijs C. van Holten, Luuk F. P. Giesen, Róbert de Jonge et al.
3 links
Diagnostics
Clinical Laboratory Practices and Quality Control
article

An Autonomous Robotic Phlebotomy Device: Extended Analytical Validation and Real-World Hemolysis Assessment

Michael A. Fouraux, Thijs C. van Holten, Luuk F. P. Giesen, Róbert de Jonge, Judith M. E. P. Gillis, Helena Chon, Martine M. L. Deckers, Jeroen A Roest, Frederique M A Koopman
article en

Abstract

Background/Objectives: Automated phlebotomy may improve preanalytical quality and access to venous blood testing. Prior work evaluating the Aletta Autonomous Robotic Phlebotomy Device (ARPD) demonstrated analytical equivalence. This study expanded the initial analytical validation to additional blood collection tubes and analytes and also assessed real-world hemolysis rates. Methods: The study was conducted in three hospital outpatient phlebotomy departments, including a site with a high prevalence of (hemato-)oncology patients. The within-subject analytical validation study included Greiner VACUETTE (Cohort 1) and BD Vacutainer (Cohort 2) serum, lithium heparin, and EDTA tubes. Equivalence of potassium, lactate dehydrogenase, hemolysis index, and complete blood count (CBC) with differential between paired ARPD-collected and manually collected samples was assessed using Passing–Bablok regression. Real-world ARPD hemolysis (>0.5 g/L free hemoglobin) rates were determined in a separate cohort (Cohort 3) and compared with site-specific manual hemolysis rates. Results: In the analytical validation study, 119 patients were included in the analysis (Cohort 1, n = 52; Cohort 2, n = 67). All tests met the predefined acceptability criteria. The hemolysis index was statistically significantly lower in ARPD-collected lithium heparin samples in Cohort 1. In real-world use (1368 ARPD venipunctures), the ARPD hemolysis rate was 0.0% (95% CI: 0.0–0.3%), significantly lower than manual phlebotomy (1.6%, p = 0.025). Conclusions: The study demonstrated analytical equivalence in a clinically complex population and found reduced ARPD hemolysis rates. The results further substantiate that the ARPD could improve patient care by reducing preanalytical errors.

DiagnosticsVol. 16(22)
Amsterdam UMC Location University of Amsterdam (NL), Albert Schweitzer Ziekenhuis (NL), St. Antonius Ziekenhuis (NL), OLVG (NL), Amsterdam Neuroscience (NL), Amsterdam University Medical Centers (NL), GGZ Oost Brabant (NL), Vrije Universiteit Amsterdam (NL), University of Amsterdam (NL), Inholland University of Applied Sciences (NL)
Good health and well-being
Clinical Laboratory Practices and Quality Control
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon